Insmed Inc (INSM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $26.58B
Last updated: Nov 17, 2026 at 11:06 AM ET
Insmed Inc (INSM) Competitors
The companies most similar to Insmed are Ascendis Pharma AS (ASND), Genmab AS (GMAB) and Revolution Medicines (RVMD). By market cap, Insmed ranks 7th of the 13 companies on this page; argenx NV ADR (ARGX) is the largest at $60.37B. The median P/E of the 6 companies with a P/E is 26.4x.
Peer Comparison
INSM's ROIC of -44.2% is below the peer median of 4.8%, and its revenue growth of 268.4% is above the median of 14.7%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Insmed (INSM) | $26.58B | N/A | 17.7x | -39.9% | -44.2% | 268.4% | 0.00% |
| Ascendis Pharma AS (ASND) | $18.06B | N/A | 13.5x | 72.9% | 12.4% | 73.0% | 0.00% |
| Genmab AS (GMAB) | $31.67B | 35.8x | 19.2x | 17.0% | 4.8% | 16.1% | 0.00% |
| Revolution Medicines Inc (RVMD) | $37.27B | N/A | 181.6x | 0.0% | -52.1% | -95.2% | 0.00% |
| Roivant Sciences Ltd (ROIV) | $28.64B | N/A | 679.3x | 0.0% | N/A | 2136.0% | 0.00% |
| Exelixis Inc (EXEL) | $16.84B | 19.3x | 6.9x | 35.4% | N/A | 10.2% | 0.00% |
| Summit Therapeutics PLC (SMMT) | $11.32B | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| BridgeBio Pharma Inc (BBIO) | $15.25B | N/A | 16.0x | -59.8% | -33.0% | 192.6% | 0.00% |
| Jazz Pharmaceuticals PLC (JAZZ) | $15.50B | 18.4x | 3.3x | 4.4% | 3.5% | 10.4% | 0.00% |
| BeOne Medicines AG (ONC) | $47.58B | 50.0x | 18.7x | 13.9% | 7.5% | 33.8% | 0.00% |
| Royalty Pharma Plc (RPRX) | $39.85B | 12.9x | 11.7x | 25.7% | 7.6% | 13.3% | 1.37% |
| Spyre Therapeutics Inc. (SYRE) | $9.88B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| argenx NV ADR (ARGX) | $60.37B | 33.5x | 6.1x | 31.7% | N/A | 52.1% | 0.00% |
| Peer median | $23.35B | 26.4x | 14.7x | 9.1% | 4.8% | 14.7% | 0.00% |
Similar Companies
These are the 12 companies most similar to Insmed, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Ascendis Pharma AS (ASND) | Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark. | ASND competitors |
| Genmab AS (GMAB) | Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark. | GMAB competitors |
| Revolution Medicines Inc (RVMD) | Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted... | RVMD competitors |
| Roivant Sciences Ltd (ROIV) | Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive... | ROIV competitors |
| Exelixis Inc (EXEL) | Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development... | EXEL competitors |
| Summit Therapeutics PLC (SMMT) | Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America... | SMMT competitors |
| BridgeBio Pharma Inc (BBIO) | BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. | BBIO competitors |
| Jazz Pharmaceuticals PLC (JAZZ) | Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United... | JAZZ competitors |
| BeOne Medicines AG (ONC) | BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe... | ONC competitors |
| Royalty Pharma Plc (RPRX) | Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. | RPRX competitors |
| Spyre Therapeutics Inc. (SYRE) | Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by... | SYRE competitors |
| argenx NV ADR (ARGX) | argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases... | ARGX competitors |
Frequently Asked Questions About INSM
Who are Insmed's main competitors?
The companies most similar to Insmed include Ascendis Pharma AS (ASND), Genmab AS (GMAB), Revolution Medicines (RVMD), Roivant Sciences (ROIV) and Exelixis (EXEL), listed from the closest match.
Who is Insmed's biggest competitor?
argenx NV ADR (ARGX) is the largest of the similar companies at $60.37B; Ascendis Pharma AS (ASND) is the closest match by business profile, size, sector and industry.
How does INSM stock compare with its competitors?
INSM's P/S is 17.7x against a peer median of 14.7x; its net margin is -39.9% against a peer median of 9.1%.
Which of Insmed's competitors pays a higher dividend?
Insmed pays no dividend. Royalty Pharma Plc (RPRX) has a higher forward dividend yield; Royalty Pharma Plc (RPRX) has the highest at 1.37%.
Is Insmed bigger than its competitors?
No. Insmed is 7th by market cap among the 13 companies on this page; the largest is argenx NV ADR (ARGX) at $60.37B.
INSM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts